1. Home
  2. NAMS vs REVG Comparison

NAMS vs REVG Comparison

Compare NAMS & REVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • REVG
  • Stock Information
  • Founded
  • NAMS 2019
  • REVG 2008
  • Country
  • NAMS Netherlands
  • REVG United States
  • Employees
  • NAMS N/A
  • REVG N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • REVG Auto Manufacturing
  • Sector
  • NAMS Health Care
  • REVG Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • REVG Nasdaq
  • Market Cap
  • NAMS 2.7B
  • REVG 2.9B
  • IPO Year
  • NAMS N/A
  • REVG 2017
  • Fundamental
  • Price
  • NAMS $26.73
  • REVG $59.34
  • Analyst Decision
  • NAMS Strong Buy
  • REVG Hold
  • Analyst Count
  • NAMS 10
  • REVG 4
  • Target Price
  • NAMS $41.40
  • REVG $53.00
  • AVG Volume (30 Days)
  • NAMS 984.0K
  • REVG 1.0M
  • Earning Date
  • NAMS 11-05-2025
  • REVG 09-03-2025
  • Dividend Yield
  • NAMS N/A
  • REVG 0.40%
  • EPS Growth
  • NAMS N/A
  • REVG N/A
  • EPS
  • NAMS N/A
  • REVG 2.12
  • Revenue
  • NAMS $64,006,000.00
  • REVG $2,397,000,000.00
  • Revenue This Year
  • NAMS N/A
  • REVG $3.10
  • Revenue Next Year
  • NAMS $1.67
  • REVG $7.86
  • P/E Ratio
  • NAMS N/A
  • REVG $28.01
  • Revenue Growth
  • NAMS 762.15
  • REVG N/A
  • 52 Week Low
  • NAMS $14.06
  • REVG $25.76
  • 52 Week High
  • NAMS $27.35
  • REVG $64.47
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 59.23
  • REVG 58.58
  • Support Level
  • NAMS $23.05
  • REVG $58.55
  • Resistance Level
  • NAMS $27.35
  • REVG $64.47
  • Average True Range (ATR)
  • NAMS 1.52
  • REVG 2.43
  • MACD
  • NAMS -0.11
  • REVG -0.31
  • Stochastic Oscillator
  • NAMS 85.58
  • REVG 61.08

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About REVG REV Group Inc.

REV Group Inc is a United States-based designer, manufacturer, and distributor of specialty vehicles and related aftermarket parts and services. During the first fiscal quarter of 2024, the Company formed the Specialty Vehicles Segment by combining the Fire & Emergency and Commercial segment businesses. Additionally, the Recreation segment was renamed Recreational Vehicles. As a result, the Company is now organized into two reportable segments. The company operates in the United States, Canada, and the rest of the world. Maximum of revenue is gained from Specialty Vehicles Segment.

Share on Social Networks: